It can be expected that simultaneous targeting of HER2 and uPAR, the cooperativity of which this review discusses and substantiates to contribute to the metastatic phenotype of HER2-positive BC, may possibly convert a cell's phenotype from tumorigenic to dormant or prolong their dormant state with less adverse side effects. Here, ERBB2 is linked to breast cancer.